Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, B-Cell × Proteasome Inhibitors × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 6 Recurrence 2 Lymphoma 2 Wilms Tumor 1 Plasmacytoma 1 Paraproteinemias 1 Pancreatic Neoplasms 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Leukemia, Plasma Cell 1 Leukemia, Myelomonocytic, Acute 1 Leukemia, Myeloid, Acute 1 Leukemia, Monocytic, Acute 1 Leukemia, Megakaryoblastic, Acute 1 Leukemia, Erythroblastic, Acute 1 Leukemia 1 Congenital Abnormalities 1 Carcinoma, Non-Small-Cell Lung 1 Burkitt Lymphoma 1

Interventions

Rituximab 97 Cyclophosphamide 93 fludarabine 56 Doxorubicin 29 Vincristine 27 Prednisone 27 Etoposide 25 Lenalidomide 22 ibrutinib 20 fludarabine phosphate 20 obinutuzumab 16 pembrolizumab 15 Bendamustine Hydrochloride 15 Magnetic Resonance Spectroscopy 14 Immunotherapy, Adoptive 14 Cytarabine 13 Specimen Handling 11 CT-P10 11 Bortezomib 11 polatuzumab vedotin 10 Gemcitabine 10 venetoclax 9 pirtobrutinib 9 Nivolumab 9 Carboplatin 9 Biopsy 9 zanubrutinib 8 glofitamab 8 Radiotherapy 8 Ifosfamide 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06796517 2025-01-28

Immunotherapy in Lymphoma

Seoul St. Mary's Hospital

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡